IMF Videos Search Content For Healthcare Professional (122) Healthcare Provider (122) Care Partner (75) Patient (74) Series - Any - ASCO/EHA (49) ASH (60) Ask Dr. Durie (16) Black Swan Research Initiative (5) Community Workshops (4) Emerging Therapies (6) Facebook Live (10) Health Equity (2) IMWG (3) Inspirational (3) Living Well with Myeloma (4) Myeloma in a Minute (1) Myeloma Made Simple (3) Patient & Family Webinar (4) Q&A (7) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (65) High-Risk Myeloma (42) High-risk Smoldering Myeloma (34) Late Relapse (4–6 Lines of Therapy) (81) MGUS (35) Newly Diagnosed (Pre-Treatment or First Treatment) (64) Smoldering Myeloma (50) Types of Therapy Immunomodulatory drugs (IMiDs) (58) Immunotherapies (CAR T; BiTE, etc.) (93) Monoclonal antibodies (48) Proteasome inhibitors (43) Stem cell transplant (40) Steroids (41) Supportive Care (36) Year Published 2026 (16) 2025 (38) 2024 (58) 2023 (39) 2022 (10) 2021 (7) 2020 (1) 2019 (9) 2018 (2) 2017 (1) 2016 (3) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (15) Dr. María-Victoria Mateos (6) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Dr. Saad Usmani (3) Dr. Sigurður Kristinsson (3) Dr. Shaji Kumar (2) Dr. Urvi A. Shah (2) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5DxCD3 bispecific antibody, for relapsed refractory multiple myeloma July 3, 2023 ASCO/EHA Quadruplet Induction Therapy, ASCT and MRD-modulated Consolidation and Treatment Cessation in Newly Diagnosed Multiple Myeloma July 1, 2023 ASCO/EHA Maintenance Therapy with Carfilzomib, Pomalidomide, and Dex (KPd) in High-Risk Myeloma Patients June 30, 2023 ASCO/EHA Updated Results of BCMA/CD19 Dual-targeting Fast CAR-T GC012F Dual-targeting CAR-T in RRMM June 30, 2023 ASCO/EHA Safety and Efficacy of elranatamab in RRMM & Prior BCMA Therapies: Analysis from MagnetisMM Studies June 29, 2023 ASCO/EHA CARTITUDE-4: Cilta-cel vs standard of care PVd or DPd in lenalidomide-refractory multiple myeloma June 26, 2023 ASCO/EHA Durability of Responses with Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Myeloma June 26, 2023 ASCO/EHA Comparing Health Related Quality of Life in TCE RRMM: Ide-cel vs. Standard Regimens June 26, 2023 ASCO/EHA The IMF Brings Support Group Leaders to ASH June 22, 2023 ASH DREAMM-9: Belantamab mafodotin + Standard Care in Newly Diagnosed Multiple Myeloma June 22, 2023 ASCO/EHA GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266) June 20, 2023 ASCO/EHA IDE-CEL vs Standard Regimens for High-Risk Multiple Myeloma: KARMMA-3 Analysis June 19, 2023 ASCO/EHA Load More
